PAVmed Inc. (PAVM) - Dilution Analysis

10-K filing | 0.9M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 25,086,881 → 836,229

10-Q filing | 25.1M shares outstanding

8-K filing: Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., closed on the sale of 28,750,000 shares of its common stock at $1.00 per share in an underwritten public offering, resulting in net proceeds of approximately $26.9 million, which Lucid Diagnostics intends to use for working capital and general corporate purposes. ($28.75M proceeds)

8-K filing: Veris Health Inc., a majority owned subsidiary of PAVmed Inc., sold 1,785,714 shares of common stock and warrants to purchase 1,785,714 shares of common stock at $1.40 per share, generating gross proceeds of approximately $2.5 million. ($2.5M proceeds)

10-Q filing | 17.1M shares outstanding

S-3/A filing: PAVmed Inc. is offering common stock, preferred stock, warrants, debt securities and/or units comprised of one or more of the other classes of securities offered hereby, at an aggregate initial offering price not to exceed $125,000,000.

8-K filing: Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., closed the sale of 14,375,000 shares of its common stock at $1.20 per share in an underwritten public offering, resulting in net proceeds of approximately $16.1 million. ($17.25M proceeds)

S-3/A filing: PAVmed Inc. is offering common stock, preferred stock, warrants, debt securities and/or units comprised of one or more of the other classes of securities offered hereby, at an aggregate initial offering price not to exceed $125,000,000.

S-3 filing: This S-3 filing relates to the potential offer and sale from time to time of 3,331,084 shares of the company's common stock by selling stockholders.

10-K filing | 11.5M shares outstanding

8-K filing: Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., closed on the sale of 13,939,331 shares of its common stock at a price of $1.10 per share, with estimated net proceeds of approximately $14.5 million. ($15.33M proceeds)

8-K filing: PAVmed Inc. completed an offering on February 21, 2025, selling 2,574,350 shares of common stock and pre-funded warrants to purchase 756,734 shares of common stock at $0.7115 per share, generating gross proceeds of $2.37 million, to be used for development activities and general working capital purposes. ($2.37M proceeds)

8-K filing: The company consummated the sale of 2,653 shares of its Series C Convertible Preferred Stock for approximately $2.653 million through the cancellation of certain unsecured debt obligations. ($2.65M proceeds)

8-K filing: PAVmed Inc. consummated the exchange of $22,347,543 in principal amount of its outstanding Senior Secured Convertible Notes for 22,347 shares of its Series C Convertible Preferred Stock.

S-3 filing: PAVmed Inc. files an S-3 to offer and sell shares of common stock, preferred stock, warrants, debt securities, and/or units with an aggregate initial offering price not to exceed $125,000,000.

8-K filing: PAVmed Inc. entered into a Debt Exchange Agreement to exchange Convertible Notes for Series C Preferred Stock and a Securities Purchase Agreement for the purchase of additional Series C Preferred Stock, both transactions are contingent on stockholder approval. ($25.0M proceeds)

10-Q filing | 10.0M shares outstanding

10-Q filing | 9.2M shares outstanding

10-Q filing | 8.7M shares outstanding

8-K filing: Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., entered into subscription agreements for the sale of approximately 11,634 shares of Series B-1 Convertible Preferred Stock at $1,000 per share, resulting in gross proceeds of approximately $11.6 million. ($11.6M proceeds)

10-K filing | 9.2M shares outstanding

8-K filing: Lucid Diagnostics, a subsidiary of PAVmed Inc., completed a Series B Offering and Exchange on March 13, 2024, involving the sale and exchange of Series B, Series A, and Series A-1 Convertible Preferred Stock with accredited investors. ($18.17M proceeds)

8-K filing: PAVmed Inc. distributed approximately 3,331,771 shares of common stock of Lucid Diagnostics Inc. to its stockholders through a special pro rata dividend, representing approximately 6.9% of Lucid Diagnostics' common stock outstanding.

8-K filing: PAVmed Inc. elected to receive payment of $4,675,256 of fees and reimbursements due from Lucid Diagnostics Inc. through the issuance to the Company of 3,331,771 shares of Lucid Diagnostics' common stock. ($4.68M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 111,941,269 → 7,462,751

10-Q filing | 111.9M shares outstanding

8-K filing: Lucid Diagnostics, a subsidiary of PAVmed Inc., sold 5,000 shares of Series A-1 Convertible Preferred Stock at $1,000 per share for gross proceeds of $5.0 million in a private placement that closed on October 18, 2023. ($5.0M proceeds)

10-Q filing | 104.3M shares outstanding

8-K filing: PAVmed Inc. agreed to issue 1,500,000 shares of its common stock to Sunrise Labs, Inc. in payment of a $750,000 non-refundable advance payment for continued development of the Veris Health implantable physiologic monitor. ($0.75M proceeds)

10-Q filing | 97.1M shares outstanding

10-K filing | 89.1M shares outstanding

8-K filing: Lucid Diagnostics Inc. sold 13,625 shares of Series A Convertible Preferred Stock at $1,000 per share in a private placement for gross proceeds of $13.625 million, closing on March 7, 2023. ($13.63M proceeds)

10-Q filing | 89.8M shares outstanding

10-Q filing | 87.0M shares outstanding

10-Q filing | 86.3M shares outstanding

10-K filing | 87.7M shares outstanding

8-K filing: Lucid Diagnostics Inc. entered into a Common Stock Purchase Agreement with CF Principal Investments LLC, relating to a committed equity facility, where Lucid has the right to sell up to $50.0 million in shares of Lucid's common stock to Cantor. ($50.0M proceeds)

10-Q filing | 87.9M shares outstanding

10-Q filing | 84.8M shares outstanding

8-K filing: PAVmed Inc., through its subsidiary Veris Health Inc., acquired Oncodisc Inc. by issuing approximately 19.6% of Veris' equity interests to Oncodisc Holdings in exchange for all of Oncodisc's outstanding equity interests.

10-Q filing | 83.9M shares outstanding

10-K filing | 40.5M shares outstanding

8-K filing: PAVmed Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 9,782,609 shares of common stock, with an option for the underwriter to purchase up to 1,467,391 additional shares, expecting net proceeds of approximately $41.2 million to repay debt and for working capital. ($41.2M proceeds)

8-K filing: PAVmed Inc. entered into a placement agency agreement with Maxim Group LLC and subscription agreements with investors to sell 6,000,000 shares of common stock at $2.24 per share, for gross proceeds of $13,440,000, with the offering expected to close on or about January 8, 2021. ($13.44M proceeds)

8-K filing: PAVmed Inc. closed on the sale of 5,062,500 shares of its common stock at a price of $1.60 per share. ($8.0M proceeds)

8-K filing: PAVmed Inc. entered into subscription agreements to sell 5,062,500 shares of common stock at $1.60 per share, with gross proceeds of $8,100,000, in a completed offering expected to close on or about December 22, 2020. ($8.1M proceeds)

8-K filing: PAVmed Inc. entered into a placement agency agreement and subscription agreements for an offering of 5,585,000 shares of its common stock at $1.60 per share, resulting in aggregate gross proceeds of $8,936,000, with the offering expected to close on or about December 15, 2020. ($8.94M proceeds)

10-Q filing | 40.5M shares outstanding

S-3 filing: PAVmed Inc. is offering shares of common stock, shares of preferred stock, warrants, debt securities and/or units comprised of one or more of the other classes of securities offered hereby, at an aggregate initial offering price not to exceed $75,000,000.

10-Q filing | 49.6M shares outstanding

10-Q filing | 46.9M shares outstanding

10-K filing | 40.5M shares outstanding

S-3/A filing: This S-3/A filing covers up to 9,295,510 shares of common stock that may be offered for resale by selling stockholders. The company will not receive any proceeds from the sale of these shares.